You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T cell/histiocyte-rich large B-cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

Active, not recruiting
  • ALK-Positive Large B-Cell Lymphoma
  • +34 more
  • Phoenix, Arizona
  • +32 more
Jan 3, 2023

Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

Not yet recruiting
  • Mature B-Cell Neoplasm
  • +25 more
  • (no location specified)
Sep 14, 2022

Ann Arbor Stage III DLBCL, Ann Arbor Stage IIX (Bulky) DLBCL, Ann Arbor Stage IV DLBCL Trial in United States (drug, other,

Suspended
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
  • +20 more
  • Tucson, Arizona
  • +110 more
Jan 31, 2023

DLBCL, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type Trial in Chicago (Cyclophosphamide, Doxorubicin

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Chicago, Illinois
    Northwestern University
Apr 30, 2021

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

Not yet recruiting
  • Follicular Lymphoma
  • +3 more
  • Tazemetostat Pill
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Itacitinib
  • Chimeric antigen receptor (CAR) T-cell therapy
  • Tampa, Florida
    Moffitt Cancer Center
Mar 6, 2023

Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Tampa (Comprehensive Ablative Bridging Irradiation (CABI),

Recruiting
  • Large B-cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Comprehensive Ablative Bridging Irradiation (CABI)
  • Chimeric Antigen Receptor T-Cell Therapy
  • Tampa, Florida
    Moffitt Cancer Center
Oct 26, 2023

Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

Completed
  • Diffuse Large B-cell Lymphoma
    • East Hanover, New Jersey
      Novartis
    Jun 16, 2023

    Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

    Not yet recruiting
    • Lymphoma, B-Cell
    • +7 more
    • Adaptive Bridging Radiation Therapy (ABRT)
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Aug 16, 2023

    Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • Gut microbiome analysis
    • Bologna, Italy
      Institute Of Hematology "Seràgnoli"
    Feb 10, 2023

    Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

    Suspended
    • Burkitt Lymphoma
    • +4 more
    • Rituximab
    • +6 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Lymphoma, Large B-Cell, Diffuse Trial (Cyclophosphamide, TLI, Fludarabine)

    Not yet recruiting
    • Lymphoma, Large B-Cell, Diffuse
    • (no location specified)
    Aug 18, 2023

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 30, 2022

    Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)

    Not yet recruiting
    • Large B-cell Lymphoma
    • B-cell Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Jun 29, 2023

    DLBCL - Diffuse Large B Cell Lymphoma Trial in Toronto (Cyclophosphamide, TLI)

    Recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Jul 19, 2023